News

New Experimental Model Uses Astrocytes to Test Therapies for ALS

A research team from the University of Wisconsin-Madison Waisman Center led by Su Chun Zhang, established a simple model in mice to investigate the role of human astrocytes in neurologic diseases such as Amyotrophic Lateral Sclerosis (ALS), Rett Syndrome and Huntington’s disease. The study entitled…

Genervon’s One-Patient ALS Drug Study Reveals Promising Results

Biopharmaceutical company Genervon recently reported observing improvements in a 46-year-old-man with advanced amyotrophic lateral sclerosis (ALS) taking the Company’s drug candidate GM604. The patient showed increased speech, swallowing and suction capabilities after a 12-week treatment. The drug, which has yet to be approved by the…

ALS Tissue-Engineered Skin May Hold Key to Early Diagnoses

A recent study, titled, “Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients,” published in the journal, Acta Neuropathologica Communications, details the creation of a novel tissue-engineered skin model for amyotrophic lateral sclerosis (ALS). ALS is a progressive…

ALS Ice Bucket Challenge Funds its First Research Project in Canada

The ALS Society of Canada is proud to announce the first research project on amyotrophic lateral sclerosis (ALS) to receive funding raised from the viral ALS Ice Bucket Challenge. The Society also thanks the generous support of national non-profit organization, Brain Canada, and the Canadian Government. The Arthur J. Hudson Translational Team Grant will be used to…

Inhibition of Neural Pumps May Hold Key to ALS Treatment Efficacy

Last November, Dr. Piera Pasinelli, Ph.D., associate professor of neuroscience and Co-Director of the Weinberg Unit for ALS Research at Thomas Jefferson University, and her research team made an important discovery in the field of amyotrophic lateral sclerosis (ALS) research that may change the way the therapeutic protocols…